Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation
|
|
|
- Walter Page
- 5 years ago
- Views:
Transcription
1 Major subgroups according to the World Health Organisation (WHO) Classification Myeloproliferative neoplasms (MPN) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1 (MNLE) Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation Initial diagnosis Morphology code of the first HM Major WHO subgroups and morphology codes probably referring to the same tumour as the first HM (see note 3) Mast cell sarcoma 9740/3 Other MPN (excl. 9742/3) 9742/3, 9741/3 Major WHO subgroups and morphology codes referring to potential transformation of the first HM (see note 3) Systemic mastocytosis 9741/3 See note /3, 9741/3, AML (particularly if SM-AHNMD) Mast cell leukaemia 9742/3 Other MPN, 9800/3, 9860/3 (see also note 1) Chronic myeloid leukaemia, NOS 9863/3 Other MPN, 9800/3, 9860/3, 9876/3, 9945/3, 9946/3, 9975/3 AML, 9811/3, 9835/3 9837/3, 9801/3 9809/3 Chronic myeloid leukaemia, BCR-ABL1 positive 9875/3 Other MPN, 9800/3, 9860/3 AML, 9811/3, 9835/3 9837/3, 9801/3 9809/3 Polycythaemia vera 9950/3 Other MPN MDS, AML, 9801/3 9809/3 Myeloproliferative neoplasm, NOS 9960/3 Other MPN, MD/MPN MDS, AML, 9801/3 9809/3 Primary myelofibrosis 9961/3 Other MPN, 9931/3 AML (excl 9931), 9801/3 9809/3 Essential thrombocytaemia 9962/3 Other MPN MDS, AML, 9801/3 9809/3 Chronic neutrophilic leukaemia 9963/3 Other MPN, 9800/3, 9860/3 AML, 9801/3 9809/3 Chronic eosinophilic leukaemia, NOS 9964/3 Other MPN, 9800/3, 9860/3, 9965/3, 9966/3, 9967/3 AML, 9801/3 9809/3 Myeloid and lymphoid neoplasms with PDGFRA rearrangement 9965/3 MPN, 9800/3, 9820/3, 9860/3, 9964/3, AML, 9801/3 9809/3 Myeloid neoplasms with PDGFRB rearrangement 9966/3 MPN, 9800/3, 9820/3, 9860/3, 9964/3, AML, 9801/3 9809/3 Myeloid and lymphoid neoplasms with FGFR1 rearrangement 9967/3 MPN, PLN, 9800/3, 9820/3, 9860/3, 9964/3 AML, 9801/3 9809/3 Atypical chronic myeloid leukaemia, BCR-ABL1 negative 9876/3 Other MD/MPN, MDS, MPN; 9800/3, 9860/3, 9863/3, 9960/3 AML, 9801/3 9809/3 Myelodysplastic/myeloproliferativ e neoplasms (MD/MPN) Chronic myelomonocytic leukaemia 9945/3 Other MD/MPN, MDS, 9800/3, 9860/3, 9863/3, 9960/3 AML, 9801/3 9809/3 Juvenile myelomonocytic leukaemia 9946/3 Other MD/MPN, MDS, 9800/3, 9860/3, 9863/3, 9960/3 AML, 9801/3 9809/3 Myelodysplastic/myeloproliferative neoplasm, unclassifiable 9975/3 Other MD/MPN, MDS, MPN AML, 9801/3 9809/3 Refractory anaemia 9980/3 Other MDS, 9945/3, 9975/3 AML, 9801/3, 9860/3 Refractory anaemia with ring sideroblasts 9982/3 Other MDS, 9945/3, 9975/3 AML, 9801/3, 9860/3 Refractory anaemia with excess blasts 9983/3 Other MDS, 9945/3, 9975/3 AML, 9801/3, 9860/3 Refractory cytopenia with multi-lineage dysplasia; Refractory cytopenia of childhood Myelodysplastic syndromes (MDS) 9985/3 Other MDS, 9945/3, 9975/3 AML, 9801/3, 9860/3 Myelodysplastic syndrome associated with isolated del(5q) 9986/3 Other MDS, 9945/3, 9975/3 AML, 9801/3, 9860/3 Myelodysplastic syndrome, NOS 9989/3 Other MDS, MD/MPN AML, 9801/3, 9860/3 Refractory neutropenia 9991/3 Other MDS, 9945/3, 9975/3 AML, 9801/3, 9860/3 Refractory thrombocytopenia 9992/3 Other MDS, 9945/3, 9975/3 AML, 9801/3, 9860/3
2 Blastic plasmacytoid dendritic cell neoplasm (see note 4) 9727/3 Other AML, 9800/3 9809/3, 9860/3 Acute erythroid leukaemia 9840/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia, NOS 9861/3 Other AML, 9800/3 9809/3, 9860/3, 9965/3, 9966/3, 9967/3 Acute myeloid leukaemia with t(6;9)(p23;q34); DEK-NUP /3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia (AML) and related precursor neoplasms. Acute promyelocytic leukaemia 9866/3 Other AML, 9800/3 9809/3, 9860/3 Acute myelomonocytic leukaemia 9867/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 9869/3 Other AML, 9800/3 9809/3, 9860/3 Acute basophilic leukaemia 9870/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22) CBFB-MYH /3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia with minimal differentiation 9872/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia without maturation 9873/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia with maturation 9874/3 Other AML, 9800/3 9809/3, 9860/3 Acute monoblastic and monocytic leukaemia 9891/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia with myelodysplasia-related changes 9895/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia with t(8;21)(q22;q22) RUNX1-RUNX1T1 9896/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia with t(9;11)(p22;q23); MLLT3-MLL 9897/3 Other AML, 9800/3 9809/3, 9860/3 Myeloid leukaemia associated with Down Syndrome 9898/3 Other AML, 9800/3 9809/3, 9860/3 Acute megakaryoblastic leukaemia 9910/3 Other AML, 9800/3 9809/3, 9860/3 Acute myeloid leukaemia (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 9911/3 Other AML, 9800/3 9809/3, 9860/3 Therapy-related acute myeloid leukaemia 9920/3 Other AML, 9800/3 9809/3, 9860/3; 9987/3 Myeloid sarcoma 9930/3 Other AML, 9800/3 9809/3, 9860/3 Acute panmyelosis with myelofibrosis 9931/3 Other AML, 9800/3-9809/3, 9860/3, 9961/3 Refractory anaemia with excess blasts in transition 9984/3 Other AML, 9800/3-9809/3, 9860/3 Therapy-related myelodysplastic syndrome 9987/3 Other AML, MDS
3 Precursor lymphoid neoplasms (PLN) Mature B-cell neoplasms (MBCN), indolent B lymphoblastic lymphoma 9728/3 T lymphoblastic lymphoma 9729/3 Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9702/3 B lymphoblastic leukaemia/lymphoma, NOS 9811/3 B lymphoblastic leukaemia/lymphoma with t(9;22)(q34;q11.2); BCR- ABL1 B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL rearranged B lymphoblastic leukaemia/lymphoma with t(12;21)(p13;q22); TEL- AML1 (ETV6-RUNX1) 9812/3 9813/3 9814/3 B lymphoblastic leukaemia/lymphoma with hyperdiploidy 9815/3 B lymphoblastic leukaemia/lymphoma with hypodiploidy (Hypodiploid ALL) B lymphoblastic leukaemia/lymphoma with t(5;14)(q31;q32); IL3- IGH B lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3); E2A- PBX1 (TCF3-PBX1) 9816/3 9817/3 Lymphoblastic leukaemia/lymphoma, NOS 9835/3 B lymphoblastic leukaemia 9836/3, 9702/3 T lymphoblastic leukaemia/lymphoma 9837/3 Other PLN, 9590/3, 9591/3, 9800/3-9809/3, 9820/3, 9702/3 Primary cutaneous follicle centre lymphoma 9597/3 9590/3, 9591/3, 9690/3, 9691/3, 9695/3, 9698/3 Small lymphocytic lymphoma 9670/3 9590/3, 9591/3, 9671/3, 9689/3, 9690/3, 9691/3, 9695/3, 9699/3, 9760/3, 9761/3, 9762/3, 9800/3, 9820/3, 9823/3, 9940/3 Chronic lymphocytic leukaemia 9823/3 9590/3, 9591/3, 9670/3, 9671/3, 9689/3, 9690/3, 9691/3, 9695/3, 9699/3, 9800/3, 9820/3, 9940/3 9680/3, /3, /3 9680/3, /3, /3 Lymphoplasmacytic lymphoma 9671/3 9590/3, 9591/3, 9670/3, 9760/3, 9761/3, 9762/3, PCN 9680/3, /3, /3 Waldenström macroglobulinemia 9761/3 9590/3, 9591/3, 9670/3, 9671/3, 9760/3, 9762/3, PCN 9680/3, /3, /3 Splenic marginal zone lymphoma 9689/3 9590/3, 9591/3, 9670/3, 9699/3 9680/3 Follicular lymphoma, NOS 9690/3 9590/3, 9591/3, 9597/3, 9670/3, 9691/3, 9695/3, 9698/3 9680/3, 9687/3, 9826/3, 9836/3, 9728/3, 9811/3- Follicular lymphoma, grade /3 9590/3, 9591/3, 9597/3, 9670/3, 9690/3, 9695/3, 9698/3 9680/3, 9687/3, 9826/3, 9836/3, 9728/3, 9811/3- Follicular lymphoma, grade /3 9590/3, 9591/3, 9597/3, 9670/3, 9690/3, 9691/3, 9698/3 9680/3, 9687/3, 9826/3, 9836/3, 9728/3, 9811/3- Marginal zone lymphoma 9699/3 9590/3, 9591/3, 9670/3, 9689/3 9680/3, Heavy chain disease 9762/3 9590/3, 9591/3, 9670/3, 9671/3, 9760/3, 9761/3, PCN 9680/3, Immunoproliferative small intestinal disease 9764/3 9590/3, 9591/3,9760/3 9680/3 Hairy cell leukaemia 9940/3 9590/3, 9591/3, 9670/3, 9800/3, 9820/3, 9823/3 9680/3 Mantle cell lymphoma 9673/3 9590/3, 9591/3, 9596/3, 9675/3, 9680/3, 9800/3, 9820/3
4 Mature B-cell neoplasms (MBCN), aggressive Primary effusion lymphoma 9678/3 Primary mediastinal large B-cell lymphoma 9679/3 Diffuse large B-cell lymphoma 9680/3 Diffuse large B-cell lymphoma, immunoblastic 9684/3 Burkitt lymphoma 9687/3 T-cell/histiocyte rich large B-cell lymphoma 9688/3 Burkitt leukaemia 9826/3 Follicular lymphoma, grade /3 Intravascular large B-cell lymphoma (C49.9) 9712/3 9590/3, 9591/3, 9596/3, 9675/3, 9679/3, 9680/3, 9684/3, 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9680/3, 9684/3, 9590/3, 9591/3, 9596/3, 9675/3, 9678/3, 9679/3, 9684/3, 9684/3, 9688/3, 9698/3, 9800/3, 9801/3, 9820/3, 9826/3, 9712/3, 9735/3, 9737/3, 9738/3, 9835/3 9590/3, 9591/3, 9596/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9698/3, 9675/3, 9712/3, 9735/3, 9737/3, 9738/3 9590/3, 9591/3, 9596/3, 9678/3, 9679/3, 9680/3, 9684/3, 9687/3, 9688/3, 9800/3, 9801/3, 9805/3-9809/3, 9820/3, 9712/3, 9735/3, 9737/3, 9738/3, 9835/3 9684/3, 9687/3, 9688/3, 9690/3, 9691/3, 9695/3, 9712/3, 9735/3, 9737/3, 9738/3, 9597/3 9684/3, 9687/3, 9688/3, 9698/3, 9735/3, 9737/3, 9738/3 Plasmablastic lymphoma 9735/3 ALK positive large B-cell lymphoma 9737/3 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9737/3, 9738/3, PCN 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9738/3 Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease 9738/3 9684/3, 9687/3, 9688/3, 9698/3, 9712/3, 9735/3, 9737/3 B-cell prolymphocytic leukaemia 9833/3 9590/3, 9591/3, 9800/3, 9820/3, 9823/3, 9832/3
5 Solitary plasmacytoma of bone 9731/3 9671/3, 9734/3, 9735/3, 9761/3, 9762/3 9732/3; 9733/3 Mature B-cell neoplasms, plasma cell neoplasms (PCN) Mature T-cell and NK-cell neoplasms (MTCN) Hodgkin lymphoma (HL) Plasma cell myeloma 9732/3 9671/3, 9731/3, 9734/3, 9735/3, 9761/3, 9762/3 9733/3 Plasma cell leukaemia 9733/3 9671/3, 9731/3, 9732/3, 9734/3, 9735/3, 9761/3, 9762/3, 9800/3, 9801/3, 9820/3, Extraosseous plasmacytoma 9734/3 9671/3, 9731/3, 9735/3, 9761/3, 9762/3 9732/3; 9733/3 Mycosis fungoides 9700/3 Other MTCN (excl. 9702/3), 9590/3, 9591/3 9702/3, 9727/3, 9729/3, 9835/3, 9837/3 Sézary syndrome 9701/3 Other MTCN, 9590/3, 9591/3 (Peripheral) T-cell lymphoma, NOS 9702/3 Other MTCN, 9590/3, 9591/3, 9727/3, 9729/3, 9835/3, 9837/3 Angioimmunoblastic T-cell lymphoma 9705/3 Other MTCN, 9590/3, 9591/3 Subcutaneous panniculitis-like T-cell lymphoma 9708/3 Other MTCN, 9590/3, 9591/3 Cutaneous T-cell lymphoma, NOS 9709/3 Other MTCN (excl. 9702/3), 9590/3, 9591/3 9702/3, 9727/3, 9729/3, 9835/3, 9837/3 Anaplastic large cell lymphoma, ALK positive 9714/3 Other MTCN, 9590/3, 9591/3 Hepatosplenic T-cell lymphoma 9716/3 Other MTCN, 9590/3, 9591/3 Enteropathy-associated T-cell lymphoma 9717/3 Other MTCN, 9590/3, 9591/3 Primary cutaneous anaplastic large cell lymphoma 9718/3 Other MTCN, 9590/3, 9591/3 Extranodal NK/T-cell lymphoma, nasal type 9719/3 Other MTCN, 9590/3, 9591/3 Systemic EBV positive T-cell lymphoproliferative disease of childhood 9724/3 Other MTCN, 9590/3, 9591/3 Hydroavacciniforme-like lymphoma 9725/3 Other MTCN, 9590/3, 9591/3 Primary cutaneous gamma-delta T-cell lymphoma 9726/3 Other MTCN, 9590/3, 9591/3 Adult T-cell leukaemia/lymphoma 9827/3 Other MTCN, 9800/3, 9801/3, 9805/3-9809/3, 9820/3 T-cell large granular lymphocytic leukaemia 9831/3 Other MTCN, 9590/3, 9591/3, 9800/3, 9820/3, 9832/3 T-cell prolymphocytic leukaemia 9834/3 Other MTCN, 9590/3, 9591/3, 9800/3, 9820/3, 9832/3 Aggressive NK-cell leukaemia 9948/3 Other MTCN, 9800/3, 9801/3, 9805/3-8909/3, 9820/3 Hodgkin lymphoma, NOS 9650/3 Other HL, 9590/3, 9596/3 Lymphocyte-rich classical Hodgkin lymphoma 9651/3 Other HL, 9590/3, 9596/3 Mixed cellularity classical Hodgkin lymphoma 9652/3 Other HL, 9590/3, 9596/3 Lymphocyte-depleted classical Hodgkin lymphoma 9653/3 Other HL, 9590/3, 9596/3 Lymphocyte-depleted classical Hodgkin lymphoma, diffuse fibrosis 9654/3 Other HL, 9590/3, 9596/3 Lymphocyte-depleted classical Hodgkin lymphoma, reticular 9655/3 Other HL, 9590/3, 9596/3 Nodular lymphocyte predominant Hodgkin lymphoma 9659/3 Other HL, 9590/3, 9596/3 9680/3 Hodgkin granuloma 9661/3 Other HL, 9590/3, 9596/3 Hodgkin sarcoma 9662/3 Other HL, 9590/3, 9596/3 Nodular sclerosis classical Hodgkin lymphoma 9663/3 Other HL, 9590/3, 9596/3 Nodular sclerosis classical Hodgkin lymphoma, cellular phase 9664/3 Other HL, 9590/3, 9596/3 Nodular sclerosis classical Hodgkin lymphoma, grade /3 Other HL, 9590/3, 9596/3 Nodular sclerosis classical Hodgkin lymphoma, grade /3 Other HL, 9590/3, 9596/3
6 Histiocytic and dendritic cell neoplasms (HDCN) Unspecified/mixed neoplasms Malignant histiocytosis, NOS 9750/3 Other HDCN Langerhans cell histiocytosis 9751/3 Other HDCN Langerhans cell histiocytosis, unifocal 9752/1 Other HDCN (see note 2) Langerhans cell histiocytosis, multifocal 9753/1 Other HDCN (see note 2) Langerhans cell histiocytosis, disseminated 9754/3 Other HDCN (see note 2) Histiocytic sarcoma 9755/3 Other HDCN Langerhans cell sarcoma 9756/3 Other HDCN Interdigitating dendritic cell sarcoma; intermediate dendritic cell tumour 9757/3 Other HDCN Follicular dendritic cell tumour 9758/3 Other HDCN Fibroblastic reticular cell tumour 9759/3 Other HDCN Lymphoma, NOS 9590/3 HL, MBCN, MTCN, PLN, 9591/3, 9596/3, 9760/3 Non-Hodgkin lymphoma, NOS 9591/3 MBCN, MTCN, PLN, 9590/3, 9596/3,9760/3 Mixed Hodgkin lymphoma and non-hodgkin lymphoma 9596/3 HL, MBCN, MTCN, PLN, 9590/3, 9591/3 Malignant lymphoma, mixed small and large cell, diffuse 9675/3 MBCN, MTCN, PLN, 9590/3, 9591/3 Immunoproliferative disease, NOS 9760/3 MBCN, 9590/3, 9591/3 Leukaemia, NOS 9800/3 9670/3, 9673/3, 9733/3, 9742/3, 9801/3-9948/3, 9963, 9964, 9965/3, 9966/3, 9967/3 Acute undifferentiated leukaemia; acute leukaemia, NOS 9801/3 9733/3, 9800/3, 9805/3, 9806/3, 9807/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3,, 9948/3, 9965/3 9966/3, PLN, AML Mixed phenotype acute leukaemia, NOS 9805/3 9800/3, 9801/3, 9806/3, 9807/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, 9860/3,, 9948/3, PLN, AML Mixed phenotype acute leukaemia with t(9;22)(q34;q11.2); BCR- 9800/3, 9801/3, 9805/3, 9807/3, 9808/3, 9809/3, 9820/3, 9806/3 ABL1 9826/3, 9827/3,, 9948/3, PLN, AML Mixed phenotype acute leukaemia with t(v;11q23); MLL rearranged 9807/3 9800/3, 9801/3, 9805/3, 9806/3, 9808/3, 9809/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML Mixed phenotype acute leukaemia, B/myeloid, NOS 9808/3 9800/3, 9801/3, 9805/3, 9806/3, 9807/3, 9809/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML Mixed phenotype acute leukaemia, T/myeloid, NOS 9809/3 9800/3, 9801/3, 9805/3, 9806/3, 9807/3, 9808/3, 9820/3, 9826/3, 9827/3, 9948/3, PLN, AML Lymphocytic leukaemia, NOS 9820/3 9670/3, 9673/3, 9733/3, 9800/3, 9801/3, 9805/3-9809/3, 9823/3-9834/3, 9940/3, 9965/3, 9966/3, 9967/3, PLN Prolymphocytic leukaemia, NOS 9832/3 9800/3, 9820/3, 9833/3, 9834/3 Myeloid leukaemia, NOS 9860/3 9742/3, 9800/3, 9801/3, 9805/3, 9840/3-9931/3, 9945/3, 9946/3, 9963/3, 9964/3, 9965/3, 9966/3, 9967/3 Note 1. In systemic mastocytosis (SM) a coexisting haematological neoplasm may be present (SM-AHNMD). Then, the disease meets the criteria for SM and the criteria for an associated, clonal haematological non-mast cell lineage disorder (MDS, MPN, AML, lymphoma or other haematological neoplasm that meet the criteria for a distinct entity in the WHO classification). This may progress/transform to acute leukaemia. Note 2. Langerhans cell histiocytosis, irrespective of the degree of dissemination, was reclassified from /1 to /3 in the 4th edition of the WHO Classification. Note 3. Even if the morphology codes mentioned in this table refer to the same tumour or to a transformation, there may be clinical evidence for a second tumour. In those (often rare) cases two tumours should be registered. For example, if a patient has a diagnosis of myeloma and a diagnosis of lymphoplasmocytic lymphoma, they may be considered as one disease, but they may also be two different diseases if there is clinical evidence for the latter, based on the type of immunoglobulins. Note 4. Morphology code 9727 was used for Precursor cell lymphoblastic lymphoma, NOS in ICD-O-3, while according to the 2011 ICD-O-3 Update this morphology code is used for Blastic plasmocytoid dendritic cell neoplasm.
2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Acute basophilic leukemia 9870/3 Acute biphenotypic leukemia [OBS] 9805/3 Acute erythroid leukemia 9840/3 Acute megakaryoblastic leukemia 9910/3 Acute monoblastic and monocytic leukemia 9891/3 Acute myeloid
2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes
Malignant lymphoma, NOS 9590/3 Non-Hodgkin lymphoma, NOS 9591/3 B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma 9596/3 Primary
Introduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues
Society for Hematopathology Scientific Symposium USCAP Companion Meeting, Boston, MA March 8, 2009 Boston, MA Steven H. Swerdlow and James Vardiman, Moderators Introduction: The Revised (4 th Edition)
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
Myeloid malignancies Chronic myeloid disorders
Myeloid malignancies Chronic myeloid disorders Myeloproliferative neoplasms (MPN) Mastocytosis / Mast cell diseases Myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement Myelodysplastic/myeloproliferative
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow*
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow* Version: Protocol Posting Date: January 2018 This protocol is NOT required for accreditation
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
Reviewing the ICD-10 classification of haematological neoplasms on its way to ICD-11
WHO-FIC NETWORK MEETING Tokyo, Japan haematological neoplasms on its way to ICD-11 Ulrich Vogel, Robert Jakob, Michael Schopen, Harald Stein, Stefan Krause Abstract: haematological neoplasms on its way
Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
Integrated Hematopathology. Morphology and FCI with IHC
Integrated Hematopathology Morphology and FCI with IHC FrontMatter.indd i 9/6/2009 9:30:12 PM FrontMatter.indd ii 9/6/2009 9:30:18 PM Integrated Hematopathology Morphology and FCI with IHC Cherie H Dunphy,
Classifications of lymphomas
Classifications of lymphomas Lukes and Collins Kiel classification Working formulation REAL classification (1994) WHO classification (2000) WHO CLASSIFICATIONF OF NEOPLASMS HAEMATOPETIC AND LYMPHOID TISSUES
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
Classification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
WHO Classification 7/2/2009
Least Malignant Myeloproliferative Disorders Myelodysplastic Syndromes Most Malignant Acute Leukemia Classifying Hematopoietic Disorders French-American-British (FAB) World Health Organization (WHO) Thanks
Hepatic Lymphoma Diagnosis An Algorithmic Approach
Hepatic Lymphoma Diagnosis An Algorithmic Approach Ryan M. Gill, M.D., Ph.D. University of California, San Francisco PLEASE TURN OFF YOUR CELL PHONES Disclosure of Relevant Financial Relationships USCAP
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow
Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms Involving the Bone Marrow Based on AJCC/UICC TNM, 7 th Edition Protocol web posting date: February 1, 2011 Procedures
Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint
Bone Marrow Protocol applies to acute leukemias, myelodysplastic syndromes, myeloproliferative disorders, chronic lymphoproliferative disorders, malignant lymphomas, plasma cell dyscrasias, histiocytic
WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia
Blood Malignancies-II Prof. Dr. Herman Hariman, a Ph.D, SpPK (KH). Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. of Clinical Pathology, School of Medicine, University of North Sumatra WHO classification
COPYRIGHTED MATERIAL. Introduction CHAPTER 1. Examination of p atients. Classification of c utaneous l ymphomas. Staging i nvestigations
CHAPTER 1 Introduction Primary cutaneous lymphomas represent distinct clinical and histopathologic subtypes of extranodal lymphomas. They can be defined as neoplasms of the immune system, characterized
Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC A. LCD ID Number: L35032 Status: A-Approved
LCD for Flow Cytometry (L35032) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12501 Contractor Type: MAC A LCD ID Number: L35032 Status: A-Approved Contractor Information LCD Information
The College of American Pathologists offers these protocols
Strategies for Laboratory and Patient Management Protocol for the Examination of Specimens From Patients With Hematopoietic Neoplasms of the Bone Marrow A Basis for Checklists LoAnn C. Peterson, MD; Steven
Contents. vii. Preface... Acknowledgments... v xiii
Contents Preface... Acknowledgments... v xiii SECTION I 1. Introduction... 3 Knowledge-Based Diagnosis... 4 Systematic Examination of the Lymph Node... 7 Cell Type Identification... 9 Cell Size and Cellularity...
Hematology Page 1 of 8
Hematology Page 1 of 8 Hematology Major Category Code Headings Revised 12/17 1 Basic methodology and test armamentarium 20000 2 Normal hematopoiesis & hemostasis 20100 3 RBC disorders, non-neoplastic 20340
Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual
Changes to the Hematopoietic and Lymphoid Neoplasm Coding Manual KCR 2018 SPRING TRAINING 2018 Hematopoietic Database Updates Updates were done to the Hematopoietic Database based on the WHO Hematopoietic
Practical Diagnosis of Hematologic Disorders. Vol 2 Malignant Disorders
5 th ed Practical Diagnosis of Hematologic Disorders Vol 2 Malignant Disorders Vol2_FrontMatter_v03_0804 final.indd i 8/6/2009 10:00:11 PM Authors Carl R Kjeldsberg, MD Professor of Pathology, University
Protocol for the Examination of Hematologic Malignancies in Bone Marrow
Protocol for the Examination of Hematologic Malignancies in Bone Marrow Version: Bone Marrow 4.0.0.0 Protocol Posting Date: February 2019 Accreditation Requirements The use of this protocol is recommended
GENETICS OF HEMATOLOGICAL MALIGNANCIES
de DUVE INSTITUTE GENETICS OF HEMATOLOGICAL MALIGNANCIES INTERUNIVERSITY CERTIFICATE IN HUMAN GENETICS Université catholique de Louvain Brussels,19/02/2016 Professor Hélène Antoine-Poirel, MD, PhD Center
Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.
Non-Hodgkin Lymphoma Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract. Protocol revision date: January 2005 No AJCC/UICC staging system Procedures Cytology
During past decades, because of the lack of knowledge
Staging and Classification of Lymphoma Ping Lu, MD In 2004, new cases of non-hodgkin s in the United States were estimated at 54,370, representing 4% of all cancers and resulting 4% of all cancer deaths,
AML: WHO classification, biology and prognosis. Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen
AML: WHO classification, biology and prognosis Dimitri Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Acute myeloid leukemia Clonal expansion of undifferentiated myeloid precursors Impaired
B980 B968. C836 Diffuse non-hodgkin's lymphoma, undifferentiated (diffuse) C839 Non-follicular diffuse non-hodgkin lymphoma, unspecified
รหะส ICD ท ยกเล ก (ตาม DRG 5.1.1) รหะสท ยกเล ก Description รหะสท ใช Description A090 Other and unspecified gastroenteritis and colitis of infectious origin A09 Diarrhoea and gastroenteritis of presumed
癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄. Agenda
癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄 Agenda Lymphocyte differentiation Classification of lymphomas Disease definitions and symptoms Tests that identify specific lymphoid histologies Staging Cancer registry
3.1 Introduction. It is emphasised that not all tests are necessarily required in every case. 3.2 Taxonomic structure
CHAPTER 3 CLASSIFICATION 3.1 Introduction Accurate diagnosis underpins lymphoma management. Historically, competing lymphoma classifications have been a source of frustration to pathologists, clinicians
Small B-cell (Histologically Low Grade) Lymphoma
Frequency of Lymphoid Neoplasms Small B-cell (Histologically Low Grade) Lymphoma Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital B-cell neoplasms 88% Diffuse large B-cell lymphoma
The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8
Heme 8 Burkitt lymphoma Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8 Most common is t(8;14) Believed to be the fastest growing tumor in humans!!!! Morphology
Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
THE SOCIETY FOR Hematopathology and the European
SPECIAL ARTICLE World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November
Corrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
HEMATOPATHOLOGY. 2017/2018 2nd semester
HEMATOPATHOLOGY 2017/2018 2nd semester NORMAL HAEMOPOESIS COMMON MYELOID PRGENITOR HEMATOPOIETIC STEM CELL COMMON LYMPHOID PROGENITOR NK T B MEGAKARYO- BLAST PRONORMO- BLAST MONOBLAST MYELOBLAST PRO NK
Plasma cell myeloma (multiple myeloma)
Plasma cell myeloma (multiple myeloma) Common lymphoid neoplasm, present at old age (70 years average) Remember: plasma cells are terminally differentiated B-lymphocytes that produces antibodies. B-cells
Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS)
Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS) Operational Policy Version 4-26.09.12 Operational Policy for the Oxford NHS/BRC SIHMDS 1. Introduction...4 1.1 Objectives...4
Update on the WHO Classification of Acute Myeloid Leukemia. Kaaren K. Reichard, MD Mayo Clinic Rochester
Update on the WHO Classification of Acute Myeloid Leukemia Kaaren K. Reichard, MD Mayo Clinic Rochester reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Objectives Present a practical
5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University
Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms Daniel A. Arber, MD Stanford University What is an integrated approach? What is an integrated approach? Incorporating all diagnostic
HEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor
HEMATOPATHOLOGY (SHANDS HOSPITAL AT THE UNIVERSITY OF FLORIDA): Rotation Director: Ying Li, M.D., Ph.D., Assistant Professor I. Description of the rotation: During this rotation, the resident will gain
Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02/17 Last Review Date: 02/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
Hematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
The spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
DETERMINATION OF A LYMPHOID PROCESS
Chapter 2 Applications of Touch Preparation Cytology to Intraoperative Consultations: Lymph Nodes and Extranodal Tissues for Evaluation of Hematolymphoid Disorders INTRODUCTION As discussed in Chap. 1,
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification Sub- Sub-ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary
Non-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Use of Immunophenotyping/ Genetic Testing in Differential Diagnosis of Mature B-Cell
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint
HEMATOLOGY Maintenance of Certification (MOC) Examination Blueprint ABIM invites diplomates to help develop the Hematology MOC exam blueprint Based on feedback from physicians that MOC assessments should
Immunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification Sub- Sub-ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary
Sub-Class Code Sub-Classification Other code Other classification. Bone Marrow failures including 7 Aplastic Anaemia 77 Other 1 Acquired
ification ification Other code Other classification Absence of T & B cells SCID 8 Inherited Disorders 1 Primary immune deficiencies Absence of T, normal B cell SCID 8 Inherited Disorders 1 Primary immune
Change Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms Version: Protocol Posting Date: October 2013 This protocol is NOT required for accreditation purposes
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes Lauren R. Teras, PhD 1 ; Carol E. DeSantis, MPH 2 ; James R. Cerhan, MD, PhD 3 ; Lindsay M. Morton, PhD 4 ; Ahmedin Jemal, DVM,
4000: Cellular Therapy Essential Data Pre-Infusion Form
4000: Cellular Therapy Essential Data Pre-Infusion Form Registry Use Only Sequence Number: Date Received: Key Fields CIBMTR Center Number: Event date: / / CIBMTR Form 4000 revision 3 (page 1 of 19). Last
Aggressive B-cell Lymphoma 2013
Aggressive B-cell Lymphoma 2013 Diffuse Large B-Cell Lymphoma Burkitt Lymphoblastic lymphoma Gray zone Intermediate DLBCL/HL Intermediate BL/DLBCL Diffuse Large B-cell lymphoma Common morphology: diffuse
The Revised 2016 WHO Classification of Acute Leukemias
The Revised 2016 WHO Classification of Acute Leukemias Robert P Hasserjian, MD Associate Professor Massachusetts General Hospital and Harvard Medical School Acute leukemias Aggressive hematopoietic neoplasms
Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham
Lymphoid Neoplasms Sylvie Freeman Department of Clinical Immunology, University of Birmingham Incidence of Haematological Malignancies UK2001 (CRUK) Malignancy New Cases All Cancers 271,000 Leukaemia 6,760
Treatments and Current Research in Leukemia. Richard A. Larson, MD University of Chicago
Treatments and Current Research in Leukemia Richard A. Larson, MD University of Chicago 2 Acute (rapid progression) Myeloid Acute myeloid leukemia (AML) Acute promyelocytic leukemia (APL) Lymphoid Acute
Common Problem Areas. WHO Classification. Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS LOW GRADE / HIGH GRADE
WHO Classification Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS REVIEW OF MOST COMMON LYMPHOMA ENTITIES Dr Stefan Dojcinov LOW GRADE / HIGH GRADE (June 2014) The Non-Hodgkin
Many of the hematolymphoid disorders are derived
REVIEW ARTICLE Practical Immunohistochemistry in Hematopathology: A Review of Useful Antibodies for Diagnosis Ji Lu, MD and Karen L. Chang, MD Abstract: This review article offers some useful panels of
MOC HEM - General Hematopathology (Mandatory 50-Question Module)
MOC HEM - General Hematopathology (Mandatory 50-Question Module) acute monoblastic/monocytic leukemia infectious mononucleosis adult T cell leukemia/lymphoma in situ follicular lymphoma ALL; phenotypes
MOC HEM - General Hematopathology (Mandatory 50-Question Module)
MOC HEM - General Hematopathology (Mandatory 50-Question Module) acute monoblastic/monocytic leukemia infectious mononucleosis adult T cell leukemia/lymphoma in situ follicular lymphoma ALL; phenotypes
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD
Meeting VAKB 8 februari 2011 Nancy Boeckx, MD, PhD What is it? clonal expansion of myeloid precursor cells with reduced capacity to differentiate as opposed to ALL/CLL, it is limited to the myeloid cell
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms
Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms Protocol applies to non-hodgkin lymphoma/lymphoid neoplasms involving any site except the ocular adnexa,
2016 WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES, 4TH ED., VOL FCDS WEBCAST SERIES OCTOBER 19, 2017
2016 WHO CLASSIFICATION OF TUMOURS OF HAEMATOPOIETIC AND LYMPHOID TISSUES, 4TH ED., VOL 2 2017-2018 FCDS WEBCAST SERIES OCTOBER 19, 2017 STEVEN PEACE, CTR 1 CDC & Florida DOH Attribution We acknowledge
Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
Kylie Lepic BSc, MD, FRCPC CAGPO Conference
Acute Leukemia Kylie Lepic BSc, MD, FRCPC CAGPO Conference Oct 19, 2013 1 Disclosures No conflicts of interest 2 Objectives Case presentation Classification of leukemia Clinical manifestations Diagnosis
88-year-old Female with Lymphadenopathy. Faizi Ali, MD
88-year-old Female with Lymphadenopathy Faizi Ali, MD Clinical History A 88-year-old caucasian female presented to our hospital with the complaints of nausea, vomiting,diarrhea, shortness of breath and
Hypereosinophili c syndrome
Hypereosinophili c syndrome Eosinophilia Eosinophilia is commonly defined as an elevated percentage of eosinophils, with an absolute eosinophil count > 500 cells per cubic millimeter Secondary Primary
Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders
Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders Definition A spectrum of related conditions originating from transformed or activated CD30-positive T-lymphocytes May coexist in individual
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota
Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota Reporting cytogenetics What is it? Terminology Clinical value What details are important Diagnostic Tools for Leukemia
Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Policy Specific Section:
Medical Policy Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Type: Medical Necessity and Investigational / Experimental Policy Specific Section:
Pathology of Hematopoietic and Lymphoid tissue
Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph
Pathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
Case year old male with abdominal lymphadenopathy Treated with 8 cycles of R-CHOP One year later B-symptoms and progressive disease
Codirectors Tsieh Sun, M.D., FASCP Francisco Vega, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Houston Texas There is no conflict of interest involved in the content and presentation
Molecular Hematopathology
Molecular Hematopathology Charles E. Hill, MD, PhD Emory University School of Medicine April 2013 The Association for Molecular Pathology Education. Innovation and Improved Patient Care. Advocacy. www.amp.org
Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation
Eosinophilia: A Diagnostic Approach and Test Utilization Strategies for Bone Marrow Evaluation American Society for Clinical Pathology 2014 Annual Meeting Presented by: Matthew T. Howard, MD Assistant
HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING. Use of IHC. Use of Polymerase Chain Reaction (PCR) Use of Flow Cytometry
HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING The 2008 WHO classification system for tumors of hematopoietic and lymphoid tissues specifies that various combinations of immunophenotypic
2 nd step do Bone Marrow Study If possible both the aspiration and
Blood Malignancies-I Prof. Herman Hariman,SpPK a (KH). Ph.D.(U.K) Prof. Dr. Adikoesoema Aman, SpPK (KH) Dept. Clinpath, FK-USU First do the Full Blood Count Hb, WBCS, Platelets Morphology!! Such as blasts,
Leukaemia Laboratory diagnosis. Dr. D.Aruna chaithanya, I yr PG(Pathology),KIMS.
Leukaemia Laboratory diagnosis Dr. D.Aruna chaithanya, I yr PG(Pathology),KIMS. Leukemia Stem cell disorder characterized by a malignant neoplastic proliferation and accumulation of immature hematopoietic
12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
SAUDI FELLOWSHIP TRAINING PROGRAM. Adult Haematology. Final Written Examination 2019
SAUDI FELLOWSHIP TRAINING PROGRAM Adult Haematology Final Written Examination 2019 Examination Format: A. The Saudi fellowship specialty final written examination shall consist of one paper with 80-120
155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary
ICD-9 TO ICD-10 Reference ICD-9 150.9 Malignant neoplasm of esophagus unspecified site C15.9 Malignant neoplasm of esophagus, unspecified 151.9 Malignant neoplasm of stomach unspecified site C16.9 Malignant
MANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
APBMT Registry LMD Disease classification sheet
AML ALL Other Acute Leukemias ACUT E LEUKEMIAS Unique Patient Number or Code: - - (yyyy - mm - dd) Classification (Check ONLY ONE): AML with recurrent genetic abnormalities Acute Lymphoblastic Leukemia
HSCT - Minimum Essential Data - A REGISTRATION - DAY 0
HSCT - Minimum Essential Data - A REGISTRATION - DAY 0 Centre Identification EBMT Code (CIC): Contact person: Hospital: Email: Unit: Patient Data Date of this report: First transplant for this patient?: